NEUTROFLOWNeutrophil Biomarker Test for Predicting Immunotherapy Benefit in Cancer Patients

This study focuses on improving the way doctors predict if cancer patients will benefit from a type of treatment called immunotherapy. Immunotherapy has changed how many cancers are treated, but it doesn't work for everyone. Currently, the tests used to decide if a patient should receive immunotherapy aren't always accurate and can require painful procedures. The NeutroFlow study aims to develop a new, more accurate, and less invasive test using blood samples to find a specific type of immune cell called Ly6Ehi neutrophils. This could help doctors make better treatment decisions, reduce unnecessary treatments, and lower healthcare costs by avoiding expensive drugs that might not work. In this study, participants will provide a blood sample before they start their treatment. Researchers will use a technology called flow cytometry to look for Ly6Ehi neutrophils in the blood. The information from these tests will be used to create a tool that predicts how well the patient will respond to the treatment. This tool will be validated by comparing its predictions with the actual outcomes of the patients' treatments over time. The study will also analyze how well the test works for different groups of people based on factors like age, gender, and cancer type, aiming to ensure it is effective for a wide range of patients.